Archives: News & Events

While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on what they do best—developing novel medicines to address unmet needs.

Every year, around 18,000 Americans will suffer a traumatic spinal cord injury. This can lead to a number of complications, including paralysis or limited movement in the limbs, spasticity and other health impacts. And right now, there are no treatments apart from physical therapy, which only has limited utility.

Ramaswamy’s latest startup, Ambros Therapeutics, launched Tuesday with plans to develop a treatment for a rare form of the chronic pain condition Complex Regional Pain Syndrome. Ambros already has a drug candidate in hand — The company has licensed neridronate from the Italian pharmaceutical company Abiogen Pharma S.p.A. 

Ahead of JP Morgan Healthcare Conference and Biotech Showcase, industry leaders gathered to reflect on the year’s developments and share their insights on what lies ahead in 2026.

Jordan Kruse realized something was wrong with her newborn, Pruitt, hours after bringing him home from the hospital last year. “He started to refuse nursing,” Kruse, 32, told The Post. “You’re supposed to nurse [newborns] every two hours, so that was my first sign.” What followed is every new parent’s biggest fear — the South … Read more

What one high-school student learned from Ben Abercrombie, who didn’t let a catastrophic injury hold him back from achieving his goals.

For 75 years, the standard tools for autoimmune disease have consisted of steroids, cytotoxics and broad biologics that tamp down the entire immune system. They can help, but they are rarely curative. “They’re blunt instruments,” Regcell Inc. CEO Mike McCullar told BioWorld. “They can’t distinguish good immune cells and bad immune cells,” which is why many … Read more